Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma.


Rituximab, a monoclonal antibody (mAb) directed against CD20, has changed practices in the treatment of patients with B-cell lymphoma. The large success of rituximab has contributed to validate immunotherapy with monoclonal antibodies as a valuable strategy in lymphoma. Recently, better-engineered anti-CD20-mAbs have been designed to improve efficacy and… (More)
DOI: 10.1007/s11912-011-0190-z


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics